HSE stroke drug delay 'quite frankly unacceptable'

A senior executive in one of the world's leading pharmaceutical companies has called the HSE's delay in approving stroke medication for reimbursement as "quite frankly unacceptable".

15th September, 2012
John Dixon of Boehringer Ingelheim: no other country has such a 'cumbersome and delaying' approval process. Photo: Maura Hickey

A senior executive in one of the world's leading pharmaceutical companies has called the Health Service Executive's delay in approving its stroke medication for reimbursement as "quite frankly unacceptable".

John Dixon, managing director of Boehringer Ingelheim UK and Ireland, told *The Sunday Business Post* that no other country had "such a cumbersome and delaying process" for approval.

It took almost a year for the HSE to approve Pradaxa for reimbursement under the public healthcare system....

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Newsround: What Thursday’s papers say